Use of recombinant flagellin in oil-in-water emulsions enhances hemagglutinin-specific mucosal IgA production and IL-17 secreting T cells against H5N1 avian influenza virus infection

Vaccine

Volumn 33, Issue 35, 2015, Pages 4321-4329

  Lai, Chih Hsuan ^a   Tang, Neos ^a   Jan, Jia Tsrong ^b   Huang, Ming Hsi ^c   Lu, Chun Yi ^d   Chiang, Bor Luen ^d   Huang, Li Min ^d   Wu, Suh Chin ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Flagellin; H5N1 vaccine; IgA; IL 17; Mucosal adjuvant

Indexed keywords

AVIAN INFLUENZA VACCINE; FLAGELLIN; HEMAGGLUTININ; IMMUNOGLOBULIN A; INTERLEUKIN 17; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; WATER OIL CREAM; EMULSION; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; SUBUNIT VACCINE; VIRUS ANTIBODY;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CERVICAL LYMPH NODE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; LIQUID; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SPLEEN CELL; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CHEMISTRY; EMULSION; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INTRANASAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; NASAL LAVAGE FLUID; ORTHOMYXOVIRIDAE INFECTIONS; SECRETION (PROCESS); VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; BRONCHOALVEOLAR LAVAGE FLUID; EMULSIONS; FEMALE; FLAGELLIN; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INTERLEUKIN-17; MICE, INBRED BALB C; NASAL LAVAGE FLUID; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT PROTEINS; SALMONELLA TYPHIMURIUM; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 84939574682     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.082     Document Type: Article

References (32)

1. Neumann G., Noda T., Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459(7249):931-939.
2. Tran T.H., Nguyen T.L., Nguyen T.D., Luong T.S., Pham P.M., Nguyen V.C., et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004, 350(12):1179-1188.
3. de Jong M.D., Simmons C.P., Thanh T.T., Hien V.M., Smith G.J., Chau T.N., et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006, 12(10):1203-1207.
4. Wang G., Zhan D., Li L., Lei F., Liu B., Liu D., et al. H5N1 avian influenza re-emergence of Lake Qinghai: phylogenetic and antigenic analyses of the newly isolated viruses and roles of migratory birds in virus circulation. J Gen Virol 2008, 89(Pt 3):697-702.
5. Rockman S., Brown L. Pre-pandemic and pandemic influenza vaccines. Hum Vaccin 2010, 6(10):792-801.
6. Watanabe Y., Ibrahim M.S., Suzuki Y., Ikuta K. The changing nature of avian influenza A virus (H5N1). Trends Microbiol 2012, 20(1):11-20.
7. Czerkinsky C., Holmgren J. Topical immunization strategies. Mucosal Immunol 2010, 3(6):545-555.
8. Kiyono H., Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004, 4(9):699-710.
9. Woodrow K.A., Bennett K.M., Lo D.D. Mucosal vaccine design and delivery. Annu Rev Biomed Eng 2012, 14:17-46.
10. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 2001, 51(1-3):21-42.
11. Devriendt B., De Geest B.G., Goddeeris B.M., Cox E. Crossing the barrier: targeting epithelial receptors for enhanced oral vaccine delivery. J Control Release 2012, 160(3):431-439.
12. Honko A.N., Mizel S.B. Effects of flagellin on innate and adaptive immunity. Immunol Res 2005, 33(1):83-101.
13. Mizel S.B., Bates J.T. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 2010, 185(10):5677-5682.
14. López-Boado Y.S., Cobb L.M., Deora R. Bordetella bronchiseptica flagellin is a proinflammatory determinant for airway epithelial cells. Infect Immun 2005, 73(11):7525-7534.
15. Wang B.Z., Quan F.S., Kang S.M., Bozja J., Skountzou I., Compans R.W. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008, 82(23):11813-11823.
16. Taylor D.N., Treanor J.J., Sheldon E.A., Johnson C., Umlauf S., Song L., et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 2012, 30(39):5761-5769.
17. Song L., Liu G., Umlauf S., Liu X., Li H., Tian H., et al. A rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of Influenza B globular head vaccines. Vaccine 2014, 32(34):4317-4323.
18. Wang B.Z., Xu R., Quan F.S., Kang S.M., Wang L., Compans R.W. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS ONE 2010, 5(11):e13972.
19. Skountzou I., Martin Mdel P., Wang B., Ye L., Koutsonanos D., Weldon W., et al. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 2010, 28(24):4103-4112.
20. Salman H.H., Irache J.M., Gamazo C. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. Vaccine 2009, 27(35):4784-4790.
21. Synnott A., Ohshima K., Nakai Y., Tanji Y. IgA response of BALB/c mice to orally administered Salmonella typhimurium flagellin-displaying T2 bacteriophages. Biotechnol Prog 2009, 25:552-558.
22. Shi W., Li Y.H., Liu F., Yang J.Y., Zhou D.H., Chen Y.Q., et al. Flagellin enhances saliva IgA response and protection of anti-caries DNA vaccine. J Dent Res 2012, 91(3):249-254.
23. Bargieri D.Y., Rosa D.S., Braga C.J., Carvalho B.O., Costa F.T., Espíndola N.M., et al. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 2008, 26(48):6132-6142.
24. Huang M.H., Lin S.C., Hsiao C.H., Chao H.J., Yang H.R., Liao C.C., et al. Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS ONE 2010, 5(8):e12279.
25. Lin S.C., Huang M.H., Tsou P.C., Huang L.M., Chong P., Wu S.C. Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS ONE 2011, 6(5):e20052.
26. Liu W.C., Lin S.C., Yu Y.L., Chu C.L., Wu S.C. Dendritic cell activation by recombinant hemagglutinin proteins of H1N1 and H5N1 influenza A viruses. J Virol 2010, 84(22):12011-12017.
27. Lu Y., Welsh J.P., Chan W., Swartz J.R. Escherichia coli-based cell free production of flagellin and ordered flagellin display on virus-like particles. Biotechnol Bioeng 2013, 110(8):2073-2085.
28. Yonekura K., Maki-Yonekura S., Namba K. Complete atomic model of the bacterial flagellar filament by electron cryomicroscopy. Nature 2003, 424(6949):643-650.
29. Smith K.D., Andersen-Nissen E., Hayashi F., Strobe K., Bergman M.A., Barrett S.L., et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003, 4(12):1247-1253.
30. Moon H.J., Lee J.S., Talactac M.R., Chowdhury M.Y., Kim J.H., Park M.E., et al. Vet Microbiol. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus 2012, 160(3-4):277-289.
31. Gupta N.K., Tomar P., Sharma V., Dixit V.K. Development and characterization of chitosan coated poly-(ε-caprolactone) nanoparticulate system for effective immunization against influenza. Vaccine 2011, 29(48):9026-9037.
32. Meng S., Liu Z., Xu L., Li L., Mei S., Bao L., et al. Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice. PLoS ONE 2011, 6(5):e19863.